Cowen & Co. Sticks to Its Hold Rating for Zafgen (ZFGN)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Zafgen (ZFGN) today. The company’s shares opened today at $10.25.

According to, Nadeau is a 5-star analyst with an average return of 8.9% and a 51.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.

Zafgen has an analyst consensus of Moderate Buy, with a price target consensus of $18.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.36 and a one-year low of $3.41. Currently, Zafgen has an average volume of 222.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders.